Across Africa the trucks rumbled, carrying precious cargo—more than 1.7 million malaria treatments. The shipments to Burundi, Liberia, Niger, and other African countries signaled a new era of lifesaving drugs made with a groundbreaking ingredient called semisynthetic artemisinin, which PATH played a central role in developing.
A dependable and affordable supply of malaria drugs is just one part of PATH’s approach to eliminating malaria.
We’re bringing the best of PATH to bear in the fight against malaria, from strengthening local health systems to advancing the world’s largest portfolio of malaria vaccine projects. Indeed, PATH is not only accelerating progress toward malaria elimination. We are leading the way.
In 2014, we began testing a number of approaches to root out malaria in Ethiopia, Senegal, and Zambia. In Zambia, we trained nearly 1,000 community health workers and data collectors who went house to house, testing and treating more than 158,000 people in just one month. Our goal is to end the cycle of transmission from human to mosquito and back again. We also expanded rapid reporting systems using mobile technology to gain real-time information and better manage any resurgences of the disease.
PATH is pioneering the use of diagnostics for malaria elimination—improving access to available tests while developing new ones that provide access to proper treatment and that can detect low levels of malaria infection that might otherwise be missed. In 2014, we increased the use of high-quality malaria diagnosis and treatment in 15 countries in Africa and the Mekong Region.
We also passed two critical milestones on the road to a malaria vaccine. The pivotal phase 3 trial of the RTS,S malaria vaccine candidate concluded in 2014, and our development partner, GlaxoSmithKline, submitted the file for regulatory review. If the vaccine candidate receives a positive opinion from European regulators, a recommendation by the World Health Organization is expected in late 2015, paving the way for subsequent decisions by African countries on vaccine adoption and introduction.
At the same time, we’re accelerating the development of more than 20 other malaria vaccine candidates and approaches—one of which could, someday, help rid the world of malaria once and for all.
To coordinate our malaria work across our innovation platforms, PATH launched a new Malaria Center of Excellence. This cross-PATH initiative will accelerate momentum toward achieving the audacious goal of a world without malaria.
PATH-pioneered approaches to malaria elimination have contributed to 4.3 million lives saved since 2000.
Key partners: National malaria programs, ministries of health, and local partners in 29 countries; African Leaders Malaria Alliance; Akros Inc.; Amyris Inc.; GlaxoSmithKline; Global Fund to Fight AIDS, Tuberculosis and Malaria; Harvard School of Public Health; Liverpool School of Tropical Medicine; Medical Care Development International; Population Services International; Roll Back Malaria Partnership; Sanofi; Save the Children; Speak Up Africa; Tulane University School of Public Health and Tropical Medicine; UK Department for International Development; United Nations Children’s Fund; United Nations Special Envoy’s Office for Malaria; University of California, Berkeley; US President’s Malaria Initiative; World Health Organization; scientists in Africa, Europe, and the United States.
Key funders: Bill & Melinda Gates Foundation; ExxonMobil Foundation; UK Department for International Development; US Agency for International Development; Vattikuti Foundation; individual contributors and family foundations.